<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BJPsych Bull</journal-id><journal-id journal-id-type="iso-abbrev">BJPsych Bull</journal-id><journal-id journal-id-type="hwp">pbrcpsych</journal-id><journal-title-group><journal-title>BJPsych Bulletin</journal-title></journal-title-group><issn pub-type="ppub">2056-4694</issn><issn pub-type="epub">2056-4708</issn><publisher><publisher-name>Royal College of Psychiatrists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4706192</article-id><article-id pub-id-type="doi">10.1192/pb.bp.114.048793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Articles</subject></subj-group></article-categories><title-group><article-title>Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Loebel</surname><given-names>Antony</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Citrome</surname><given-names>Leslie</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="A1"><label>1</label>Sunovion Pharmaceuticals, Fort Lee, New Jersey, USA</aff><aff id="A2"><label>2</label>New York Medical College, Valhalla, New York, USA</aff><author-notes><corresp id="cor1">
Correspondence to: Leslie Citrome (<email>citrome@cnsconsultant.com</email>)
</corresp><fn><p><bold>Antony Loebel</bold> MD is Chief Medical Officer at Sunovion Pharmaceuticals, Fort Lee, New Jersey, USA, and <bold>Leslie Citrome</bold> MD MPH is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College, Valhalla, New York, USA.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2015</year></pub-date><volume>39</volume><issue>5</issue><fpage>237</fpage><lpage>241</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>4</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2015 The Authors</copyright-statement><copyright-year>2015</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (<uri xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</uri>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="237.pdf"/><abstract><p id="P1">Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate. In addition to full antagonist activity at dopamine D<sub>2</sub> (<italic>K</italic><sub>i(D2)</sub> = 1 nM) and serotonin 5-HT<sub>2</sub>A (<italic>K</italic><sub>i(5-HT<sub>2</sub>A)</sub> = 0.5 nM) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-HT7 receptors (<italic>K</italic><sub>i(5-HT<sub>7</sub>)</sub> = 0.5 nM) and its partial agonist activity at 5-HT<sub>1</sub>A receptors (<italic>K</italic><sub>i(5-HT<sub>1</sub>A)</sub> = 6.4 nM). Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse. Lurasidone appears associated with minimal effects on body weight and low risk for clinically meaningful alterations in glucose, lipids or electrocardiogram parameters.</p></abstract><funding-group><award-group id="funding-1"><funding-source>Sunovion Pharmaceuticals Inc.</funding-source></award-group></funding-group></article-meta></front><body><p id="P2">Lurasidone is a second-generation antipsychotic agent that initially received regulatory approval for the treatment of adults with schizophrenia in the USA in 2010.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> In March 2014, it received marketing authorisation for this indication by the European Medicines Agency and has also been approved for the treatment of schizophrenia in Switzerland, Canada and Australia. Additionally, lurasidone recently received US and Canadian regulatory approval for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar depression), as either a monotherapy or adjunctive therapy with lithium or valproate. Detailed systematic reviews of the overall efficacy, tolerability, safety and place in therapy of lurasidone can be found elsewhere,<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> including analyses of number needed to treat (NNT) and number needed to harm (NNH).<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup></p><p id="P3">The published literature has used the US convention of describing the dose of lurasidone as the combined weight of the active drug moiety (lurasidone) plus the hydrochloride (HCl) salt, with tablet strength expressed in multiples of 20 mg. In the European Medicines Agency <italic>Summary of Product Characteristics</italic>,<sup><xref rid="R2" ref-type="bibr">2</xref></sup> tablet strength refers to the weight of active drug only, excluding the contribution from the HCl salt (<xref ref-type="table" rid="T1">Table 1</xref> shows the dose equivalence), and this dose convention will be used in the current review.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Lurasidone dose equivalents in the European Union (EU) and the USA</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="center" valign="middle" span="1"/><col align="center" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">EU doses (mg, active moiety)</th><th rowspan="1" colspan="1">US doses (mg, HCl salt)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">18.5</td><td rowspan="1" colspan="1">20</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">40</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">56<xref ref-type="table-fn" rid="TFN1"><sup>a</sup></xref></td><td rowspan="1" colspan="1">60</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">80</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">111<xref ref-type="table-fn" rid="TFN1"><sup>a</sup></xref></td><td rowspan="1" colspan="1">120</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">148<xref ref-type="table-fn" rid="TFN1"><sup>a</sup></xref></td><td rowspan="1" colspan="1">160<xref ref-type="table-fn" rid="TFN2"><sup>b</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a.</label><p>Tablet strength not available in the EU.</p></fn><fn id="TFN2"><label>b.</label><p>Tablet strength not available in the USA.</p></fn></table-wrap-foot></table-wrap><p id="P4">The purpose of this overview is to describe the pharmacodynamics and pharmacokinetics of lurasidone, and to summarise its efficacy and safety for the treatment of schizophrenia and bipolar depression based on results from both short-term and longer-term controlled clinical trials. Relevant information regarding switching and extension studies is reported, including functional and cognitive outcomes.</p><sec id="S1"><title>Pharmacodynamics and pharmacokinetics</title><p id="P5">Similar to most other second-generation antipsychotic agents, lurasidone is a full antagonist at dopamine D<sub>2</sub> and serotonin 5-HT<sub>2</sub>A receptors, with binding affinities <italic>K</italic><sub>i</sub> = 1 nM and <italic>K</italic><sub>i</sub> = 0.5 nM, respectively.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> In addition, lurasidone is distinguished by its high affinity for serotonin 5-HT<sub>7</sub> receptors (<italic>K</italic><sub>i</sub> = 0.5 nM; comparable with dopamine D<sub>2</sub> and 5-HT<sub>2</sub>A receptors) and by its partial agonist activity at 5-HT<sub>1</sub>A receptors (<italic>K</italic><sub>i</sub> = 6.4 nM).<sup><xref rid="R7" ref-type="bibr">7</xref></sup> The serotonin 5-HT<sub>7</sub> receptor is a target of interest that may be associated with the potential for both pro-cognitive and antidepressant effects,<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> whereas the 5-HT<sub>1</sub>A receptor may have a role in the treatment of major depressive disorder<sup><xref rid="R10" ref-type="bibr">10</xref></sup> and schizophrenia.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Lurasidone lacks affinity for histamine H<sub>1</sub> and muscarinic M<sub>1</sub> receptors.</p><p id="P6">The pharmacokinetic profile of lurasidone is consistent with once-daily administration, with an elimination half-life of 20&#x02013;40 h.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Mean C<sub>max</sub> and area under the curve (AUC) for lurasidone were approximately threefold and twofold greater, respectively, in a comparison of administration with food <italic>v.</italic> fasting.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Based on these data, and results from clinical trials, it is recommended that lurasidone be taken once daily in the evening, with a meal or within 30 min after eating.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Lurasidone absorption is independent of food fat content.<sup><xref rid="R12" ref-type="bibr">12</xref></sup></p><sec id="S2"><title>Metabolisation</title><p id="P7">Lurasidone is metabolised primarily via CYP3A4 and, consequently, its use is contraindicated in the presence of strong inducers and inhibitors of CYP3A4. In the presence of moderate inhibitors of CYP3A4, the recommended starting dose of lurasidone is 18.5 mg/day instead of the usual recommended 37 mg/day, and the highest recommended dose is 74 mg/day instead of the regular maximum recommended dose of 148 mg/day. Lurasidone does not affect the pharmacokinetics of other drugs including lithium, valproate or agents that are metabolised by the CYP3A4 pathway.<sup><xref rid="R13" ref-type="bibr">13</xref></sup></p><p id="P8">Examination of population subgroups based on gender, age and ethnic background did not reveal any clear evidence of differential response to lurasidone,<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> however, Asian subjects had one-and-a-half-fold increased exposure to lurasidone compared with White subjects.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Clinical studies with lurasidone did not include sufficient numbers of patients aged 65 and older to establish whether dose adjustment is necessary on the basis of age alone. In patients with moderate or severe renal or hepatic impairment, the recommended starting dose is 18.5 mg/day; the maximum dose should not exceed 74 mg/day in moderate to severe renal impairment or moderate hepatic impairment and 37 mg/day in severe hepatic impairment.</p></sec></sec><sec id="S3"><title>Efficacy in schizophrenia</title><sec id="S4"><title>Acute treatment</title><p id="P9">Based on a robust registration programme that included five informative and similarly designed 6-week, fixed-dose, placebo-controlled studies,<sup><xref rid="R14" ref-type="bibr">14</xref>-<xref rid="R18" ref-type="bibr">18</xref></sup> lurasidone is approved for the treatment of schizophrenia within a dose range of 37&#x02013;148 mg/day. Reductions in the Brief Psychiatric Rating Scale<sup><xref rid="R19" ref-type="bibr">19</xref></sup> or Positive and Negative Syndrome Scale (PANSS)<sup><xref rid="R20" ref-type="bibr">20</xref></sup> total scores were consistently greater for lurasidone compared with placebo across the approved dose range. A starting dose of 37 mg/day has demonstrated significant efficacy, thus no initial dose titration is necessary. Subsequent dose increases can be made based on clinician judgement, typically in increments of 37 mg at approximately weekly intervals. Patients with suboptimal symptom control at lower doses of lurasidone may benefit from higher doses. The NNT of lurasidone (<italic>v.</italic> placebo) for a &#x02265;30% reduction in PANSS total score was 4 (95% CI 3&#x02013;5) for lurasidone 148 mg/day compared with 6 (95% CI 5&#x02013;10) at 37 mg/day.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p><p id="P10">The short-term effectiveness of lurasidone has also been evaluated in a study in which clinically stable but symptomatic out-patients with schizophrenia or schizoaffective disorder were switched from their current antipsychotic medication to lurasidone in a 6-week study that examined the efficacy and tolerability of three different dosing strategies (starting at 37 mg/day for 2 weeks, <italic>v.</italic> starting at 74 mg/day for 2 weeks, <italic>v.</italic> starting at 37 mg/day for 1 week followed by 74 mg/day the second week).<sup><xref rid="R21" ref-type="bibr">21</xref></sup> The primary outcome was time to treatment failure, defined as any occurrence of insufficient clinical response, exacerbation of underlying disease or discontinuation due to an adverse event. No clinically relevant differences were observed among the three groups in efficacy or tolerability outcomes; treatment failure rates were low for all three switch groups (~8%).</p></sec><sec id="S5"><title>Long-term treatment</title><p id="P11">Longer-term data for lurasidone in patients with schizophrenia are available based on randomised, double-blind, 12-month trials that include comparisons with risperidone in a safety study,<sup><xref rid="R22" ref-type="bibr">22</xref></sup> and quetiapine extended-release (XR) in a double-blind extension to one of the short-term pivotal trials.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> In the risperidone comparator study, treatment with lurasidone was associated with comparable improvement in efficacy, with similar relapse rates at 12 months. In the quetiapine XR comparator study, lurasidone was non-inferior to quetiapine XR in risk for relapse. At 12 months, treatment with lurasidone (modal daily dose 111 mg) was associated with a significantly greater improvement in PANSS total score compared with quetiapine XR (modal daily dose 600 mg), numerically lower risk of relapse (23.7% <italic>v.</italic> 33.6%; <italic>P</italic> = 0.280; <xref ref-type="fig" rid="F1">Fig. 1a</xref>), significantly lower risk of re-hospitalisation at 12 months (9.8% <italic>v.</italic> 23.1%; log-rank <italic>P</italic> = 0.049; <xref ref-type="fig" rid="F1">Fig. 1b</xref>) and significantly higher rates of remission (61.9% <italic>v.</italic> 46.3%; <italic>P</italic> = 0.043; <xref ref-type="fig" rid="F1">Fig. 1c</xref>). In the same study, a computerised cognitive battery (Cogstate; <uri xlink:href="http://cogstate.com">http://cogstate.com</uri>) was administered at the end of 6 weeks of acute double-blind treatment and after 6 months of double-blind extension treatment. At both time points, treatment with lurasidone was associated with significantly greater improvement in cognition compared with quetiapine XR, with a moderate effect size.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p><fig id="F1" orientation="portrait" position="float"><label>Fig 1</label><caption><p>Kaplan&#x02013;Meier estimates of the risk of relapse and rehospitalisation during 12 months of treatment with lurasidone <italic>v</italic>. quetiapine extended release (XR): a. probability of relapse; b. probability of rehospitalisation; c. cumulative remission.</p></caption><graphic xlink:href="239f1"/></fig><p id="P12">The long-term effectiveness of lurasidone in the treatment of schizophrenia has also been evaluated in two open-label extension studies. In the first, a 6-month extension of the switch study summarised above,<sup><xref rid="R25" ref-type="bibr">25</xref></sup> the mean PANSS total score continued to show improvement. Moreover, low rates were observed for both psychiatric emergency services utilisation (mean: 0.8% per month) and contact with the criminal justice system (mean: 1.8% per month).<sup><xref rid="R25" ref-type="bibr">25</xref></sup> In a second open-label extension study in which patients received 6 months of treatment with lurasidone, antipsychotic efficacy was maintained, with further reduction observed in mean PANSS total scores, in patients who had initially received lurasidone, olanzapine or placebo during the acute treatment phase.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p id="P13">Preliminary results of a double-blind, randomised withdrawal study examining the maintenance of efficacy of lurasidone treatment in patients with chronic schizophrenia have been presented.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Patients experiencing an acute exacerbation of schizophrenia received flexible doses of lurasidone (37 or 74 mg/day) during a 12- to 24-week open-label stabilisation phase. Those who maintained clinical stability for &#x02265;12 weeks entered a 28-week, double-blind withdrawal phase and were randomised to receive either lurasidone (at the same dose they were receiving at completion of the stabilisation phase) or placebo. Lurasidone significantly delayed time to relapse compared with placebo (log-rank test <italic>P</italic> = 0.039) and was associated with a 34% reduction in risk of relapse (Cox proportional hazard model ratio 0.66 (95% CI 0.45&#x02013;0.98); <italic>P</italic> = 0.041).</p></sec><sec id="S6"><title>Tolerability and safety</title><p id="P14">Commonly observed adverse reactions in short-term trials in schizophrenia (incidence on lurasidone &#x02265;5% and twofold greater than placebo) were somnolence (17% <italic>v.</italic> 7%; NNH = 10), akathisia (13% <italic>v.</italic> 3%; NNH = 10), nausea (10% <italic>v.</italic> 5%; NNH = 20) and extrapyramidal symptoms (excluding akathisia and restlessness) 14% <italic>v.</italic> 6% (NNH = 13).<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Akathisia and extrapyramidal symptoms appear dose related within the dose range of 18.5 to 111 mg/day.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> The frequency of akathisia in patients with schizophrenia was 5.6% for 18.5 mg, 10.7% for 37 mg, 12.3% for 74 mg and 22.0% for 111 mg. In a study where lurasidone was administered in the evening,<sup><xref rid="R18" ref-type="bibr">18</xref></sup> akathisia was reported by 7.4% of patients receiving lurasidone 148 mg/day. It is possible that evening dose administration is associated with more favourable tolerability overall relative to morning dosing. Adverse event frequencies (including movement disorders) reported in the bipolar depression programme, where lurasidone was dosed at night in all studies, were generally lower than observed in patients with schizophrenia.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> The mean change in weight observed across 6-week trials in schizophrenia was +0.43 kg for lurasidone <italic>v.</italic> &#x02212;0.02 kg for placebo.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> In contrast, mean change in weight was +4.15 kg for olanzapine and +2.09 kg for quetiapine XR in 6-week trials where these agents served as active controls.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> In 6-week trials, the proportion of patients with a clinically meaningful (&#x02265;7%) endpoint increase in body weight was 4.8% for lurasidone <italic>v.</italic> 3.3% for placebo (NNH = 67; not significant).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> In contrast, the proportion of patients with clinically significant weight gain during short-term treatment in one comparator study with olanzapine <italic>v.</italic> placebo was 34% <italic>v.</italic> 7% (NNH = 4);<sup><xref rid="R17" ref-type="bibr">17</xref></sup> and the proportion of patients with clinically significant weight gain in a second comparator study with quetiapine XR <italic>v.</italic> placebo was 15% <italic>v.</italic> 3% (NNH = 8).<sup><xref rid="R18" ref-type="bibr">18</xref></sup> The proportion of patients with clinically significant weight gain on lurasidone was similar to the rate for placebo in both comparator studies (NNH&#x0003e;55).<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup></p><p id="P15">Longer-term studies for lurasidone are consistent with short-term findings regarding changes in body weight; in a long-term study lurasidone was associated with a mean change in weight of +0.73 kg at month 12, compared with +1.23 kg on quetiapine XR.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><p id="P16">The short-term effect of lurasidone on metabolic variables appears minimal.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> In pooled short-term (6-week) clinical trials, the mean last observation carried forward (LOCF)-endpoint change in total fasting cholesterol was &#x02212;0.15 mmol/L for lurasidone and &#x02212;0.16 mmol/L for placebo;<sup><xref rid="R28" ref-type="bibr">28</xref></sup> for fasting triglycerides it was &#x02212;0.15 mmol/L for lurasidone and &#x02212;0.17 mmol/L for placebo;<sup><xref rid="R28" ref-type="bibr">28</xref></sup> and for fasting glucose it was +0.07 mmol/L for lurasidone and +0.03 mmol/L for placebo.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Long-term data regarding metabolic outcomes extending out to 12 months are consistent with the short-term data.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> In long-term studies,<sup><xref rid="R28" ref-type="bibr">28</xref></sup> mean LOCF-endpoint change on lurasidone was &#x02212;0.08 mmol/L for total fasting cholesterol, &#x02212;0.08 mmol/L for fasting triglycerides and +0.11 mmol/L for fasting glucose.</p><p id="P17">A moderate dose-dependent increase in prolactin was observed in patients treated with lurasidone, with more pronounced effects in female than in male patients; however, the increase was lower than what is observed with risperidone and haloperidol. In a randomised, 12-month, double-blind safety study comparing lurasidone with risperidone, mean change from baseline to endpoint in serum prolactin levels in men was +2.51 ng/ml for lurasidone and +9.45 ng/ml for risperidone, and in women it was +5.16 ng/ml for lurasidone and +33.90 ng/ml for risperidone.<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p><p id="P18">Serial electrocardiograms during short-term and long-term trials indicate that lurasidone, at doses as high as 558 mg/day, does not have a clinically meaningful impact on the QT interval.<sup><xref rid="R1" ref-type="bibr">1</xref></sup></p></sec></sec><sec id="S7"><title>Bipolar depression</title><p id="P19">There is an unmet need for efficacious and tolerable treatments for bipolar depression. Patients with bipolar disorder spend most of their symptomatic time in the depressed phase of their illness.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> While multiple agents are approved for the treatment of bipolar mania, there is a paucity of approved medications for the treatment of bipolar depression.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> The older interventions (quetiapine and olanzapine&#x02013;fluoxetine combination) are as likely to provide therapeutic benefit as adverse effects.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Cross-study comparisons in populations with bipolar depression suggest that treatment with lurasidone is associated with less sedation than quetiapine and less weight gain than the olanzapine&#x02013;fluoxetine combination.<sup><xref rid="R30" ref-type="bibr">30</xref></sup></p><p id="P20">Lurasidone, in the dose range of 18.5&#x02013;111 mg/day, demonstrated superiority <italic>v.</italic> placebo in two 6-week, randomised, double-blind, placebo-controlled, flexibly-dosed acute studies in patients with major depressive episodes associated with bipolar I disorder, one using lurasidone monotherapy and the other using lurasidone adjunctive with lithium or valproate.<sup><xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup> As reported by Citrome and colleagues,<sup><xref rid="R6" ref-type="bibr">6</xref></sup> monotherapy treatment with lurasidone (<italic>v.</italic> placebo) was associated with an NNT of 5 (95% CI 4&#x02013;8) for treatment response, defined as &#x02265;50% reduction from baseline on Montgomery-&#x000c5;sberg Depression Rating Scale<sup><xref rid="R33" ref-type="bibr">33</xref></sup> (MADRS) total score; adjunctive therapy with lurasidone was associated with an NNT of 7 (95%, CI 4&#x02013;24). NNT for remission, defined as a final MADRS total score &#x02264;12, was 7 (95% CI 4&#x02013;14) for lurasidone monotherapy and 7 (95% CI 4&#x02013;23) for adjunctive lurasidone. These results are comparable with NNT values reported for quetiapine (6 for response, 6 for remission) and olanzapine-fluoxetine combination (4 for response, 5 for remission).</p><p id="P21">Lurasidone was not associated with clinically meaningful mean weight or metabolic changes compared with placebo in these bipolar depression studies. This is in contrast to olanzapine-fluoxetine combination where the NNH (<italic>v.</italic> placebo) was 6 for clinically meaningful weight gain (&#x02265;7% from baseline).<sup><xref rid="R6" ref-type="bibr">6</xref></sup> The three most frequently occurring adverse events with the largest difference in incidence for lurasidone <italic>v.</italic> placebo were nausea (NNH = 17 for monotherapy, NNH = 16 for adjunctive therapy), akathisia (NNH = 15 for monotherapy, NNH = 30 for adjunctive therapy) and somnolence (NNH = 25 for monotherapy, NNH = 19 for adjunctive therapy).<sup><xref rid="R6" ref-type="bibr">6</xref></sup> The high NNH of lurasidone for somnolence compares favourably with the NNH of 3 (95% CI 2.2&#x02013;2.7) reported for quetiapine in studies of bipolar depression, regardless of formulation or dose.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p id="P22">Overall, the results of double-blind trials indicate that lurasidone has a highly favourable benefit/risk ratio for the treatment of bipolar I depression, with &#x02018;single-digit&#x02019; NNT (indicating significant efficacy) and &#x02018;double-digit&#x02019; or higher NNH (indicating high tolerability).</p></sec><sec id="S8"><title>Summary</title><p id="P23">Lurasidone represents a new addition to the pharmacological armamentarium available for the treatment of serious mental disorders. It has demonstrated efficacy in the treatment of schizophrenia, within the dose range of 37&#x02013;148 mg/day, and bipolar depression, within the dose range of 18.5&#x02013;111 mg/day. Across both indications, treatment with lurasidone appears associated with minimal effects on body weight and low risk for clinically meaningful alterations in glucose, lipids or ECG parameters. Lurasidone's combination of efficacy in schizophrenia and bipolar depression with minimal metabolic disturbance and little effect on movement disorders and prolactin represents a potentially important clinical advance.<sup><xref rid="R34" ref-type="bibr">34</xref></sup></p></sec></body><back><fn-group><fn fn-type="conflict"><p><bold>Declaration of interest</bold> A.L. is a full-time employee of Sunovion Pharmaceuticals. In the past 12 months, L.C. was a consultant for, has received honoraria from, or has conducted clinical research supported by: Actavis (Forest Laboratories), Alexza Pharmaceuticals, Alkermes, AstraZeneca, Bristol-Myers Squibb, Eli Lilly &#x00026; Company, Forum Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Medivation, Merck Worldwide, Mylan Laboratories, Novartis Pharmaceuticals, Noven Pharmaceuticals, Otsuka Pharmaceutical Group, Pfizer, Reckitt Benckiser, Reviva Pharmaceuticals, Shire, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding</bold></p><p>This work was supported by <funding-source>Sunovion Pharmaceuticals Inc.</funding-source>, Marlborough, Massachusetts and Fort Lee, New Jersey.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Sunovion</collab></person-group>
<source>Latuda (Lurasidone HCl) Tablets: Highlights of Prescribing Information</source>. <publisher-name>Sunovion</publisher-name>, <year>2013</year> (<uri xlink:href="http://www.latuda.com/LatudaPrescribingInformation.pdf">http://www.latuda.com/LatudaPrescribingInformation.pdf</uri>).
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group>
<source>Latuda: EPAR &#x02013; Product Information. Annex I: Summary of Product Characteristics</source>. <publisher-name>EMA</publisher-name>, <year>2014</year> (<uri xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf</uri>).
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L</given-names></name></person-group>
<article-title>Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic</article-title>. <source>Int J Clin Pract</source>
<year>2011</year>; <volume>65</volume>: <fpage>189</fpage>-<lpage>210</lpage>.
<pub-id pub-id-type="pmid">21129135</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L</given-names></name></person-group>
<article-title>Lurasidone in schizophrenia: new information about dosage and place in therapy</article-title>. <source>Adv Ther</source>
<year>2012</year>; <volume>29</volume>: <fpage>815</fpage>-<lpage>25</lpage>.
<pub-id pub-id-type="pmid">23001538</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L</given-names></name></person-group>
<article-title>Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed</article-title>? <source>Clin Schizophr Relat Psychoses</source>
<year>2012</year>; <volume>6</volume>: <fpage>76</fpage>-<lpage>85</lpage>.
<pub-id pub-id-type="pmid">22776634</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L</given-names></name><name><surname>Ketter</surname><given-names>TA</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Loebel</surname><given-names>A</given-names></name></person-group>
<article-title>Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed</article-title>. <source>J Affect Disord</source>
<year>2014</year>; <volume>155</volume>: <fpage>20</fpage>-<lpage>7</lpage>.
<pub-id pub-id-type="pmid">24246116</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>T</given-names></name><name><surname>Horisawa</surname><given-names>T</given-names></name><name><surname>Tokuda</surname><given-names>K</given-names></name><name><surname>Ishiyama</surname><given-names>T</given-names></name><name><surname>Ogasa</surname><given-names>M</given-names></name><name><surname>Tagashira</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity</article-title>. <source>J Pharmacol Exp Ther</source>
<year>2010</year>; <volume>334</volume>: <fpage>171</fpage>-<lpage>81</lpage>.
<pub-id pub-id-type="pmid">20404009</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horiguchi</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group>
<article-title>The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats</article-title>. <source>J Pharmacol and Exp Ther</source>
<year>2011</year>; <volume>338</volume>: <fpage>605</fpage>-<lpage>14</lpage>.
<pub-id pub-id-type="pmid">21558435</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cates</surname><given-names>LN</given-names></name><name><surname>Roberts</surname><given-names>AJ</given-names></name><name><surname>Huitron-Resendiz</surname><given-names>S</given-names></name><name><surname>Hedlund</surname><given-names>PB</given-names></name></person-group>
<article-title>Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype</article-title>. <source>Neuropharmacology</source>
<year>2013</year>; <volume>70</volume>: <fpage>211</fpage>-<lpage>7</lpage>.
<pub-id pub-id-type="pmid">23416039</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blier</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>NM</given-names></name></person-group>
<article-title>Is there a role for 5-HT1A agonists in the treatment of depression?</article-title>
<source>Biol Psychiatry</source>
<year>2003</year>; <volume>53</volume>: <fpage>193</fpage>-<lpage>203</lpage>.
<pub-id pub-id-type="pmid">12559651</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohno</surname><given-names>Y</given-names></name></person-group>
<article-title>Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease</article-title>. <source>CNS Neurosci Ther</source>
<year>2011</year>; <volume>17</volume>: <fpage>58</fpage>-<lpage>65</lpage>.
<pub-id pub-id-type="pmid">21091640</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Preskorn</surname><given-names>S</given-names></name><name><surname>Ereshefsky</surname><given-names>L</given-names></name><name><surname>Chiu</surname><given-names>YY</given-names></name><name><surname>Poola</surname><given-names>N</given-names></name><name><surname>Loebel</surname><given-names>A</given-names></name></person-group>
<article-title>Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies</article-title>. <source>Hum Psychopharmacol</source>
<year>2013</year>; <volume>28</volume>: <fpage>495</fpage>-<lpage>505</lpage>.
<pub-id pub-id-type="pmid">24014143</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiu</surname><given-names>YY</given-names></name><name><surname>Ereshefsky</surname><given-names>L</given-names></name><name><surname>Preskorn</surname><given-names>SH</given-names></name><name><surname>Poola</surname><given-names>N</given-names></name><name><surname>Loebel</surname><given-names>A</given-names></name></person-group>
<article-title>Lurasidone drug-drug interaction studies: a comprehensive review</article-title>. <source>Drug Metabol Drug Interact</source>
<year>2014</year>; <day>12</day>
<month>5</month>
<comment>[Epub ahead of print]</comment>.
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogasa</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Guarino</surname><given-names>J</given-names></name></person-group>
<article-title>Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study</article-title>. <source>Psychopharmacology (Berl)</source>
<year>2013</year>; <volume>225</volume>: <fpage>519</fpage>-<lpage>30</lpage>.
<pub-id pub-id-type="pmid">22903391</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ogasa</surname><given-names>M</given-names></name><name><surname>Guarino</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Severs</surname><given-names>J</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial</article-title>. <source>J Clin Psychiatry</source>
<year>2009</year>; <volume>70</volume>: <fpage>829</fpage>-<lpage>36</lpage>.
<pub-id pub-id-type="pmid">19497249</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nasrallah</surname><given-names>HA</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study</article-title>. <source>J Psychiatr Res</source>
<year>2013</year>; <volume>47</volume>: <fpage>670</fpage>-<lpage>7</lpage>.
<pub-id pub-id-type="pmid">23421963</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>HY</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Ogasa</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study</article-title>. <source>Am J Psychiatry</source>
<year>2011</year>; <volume>168</volume>: <fpage>957</fpage>-<lpage>67</lpage>.
<pub-id pub-id-type="pmid">21676992</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loebel</surname><given-names>A</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Kalali</surname><given-names>AH</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial</article-title>. <source>Schizophr Res</source>
<year>2013</year>; <volume>145</volume>: <fpage>101</fpage>-<lpage>9</lpage>.
<pub-id pub-id-type="pmid">23415311</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Overall</surname><given-names>JE</given-names></name><name><surname>Gorham</surname><given-names>DR</given-names></name></person-group>
<article-title>The Brief Psychiatric Rating Scale</article-title>. <source>Psychol Rep</source>
<year>1962</year>; <volume>10</volume>: <fpage>799</fpage>-<lpage>812</lpage>.
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>LA</given-names></name></person-group>
<article-title>The Positive and Negative Syndrome Scale (PANSS) for schizophrenia</article-title>. <source>Schizophr Bull</source>
<year>1987</year>; <volume>13</volume>: <fpage>261</fpage>-<lpage>76</lpage>.
<pub-id pub-id-type="pmid">3616518</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>JP</given-names></name><name><surname>Citrome</surname><given-names>L</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Pikalov</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study</article-title>. <source>J Clin Psychiatry</source>
<year>2013</year>; <volume>74</volume>: <fpage>170</fpage>-<lpage>9</lpage>.
<pub-id pub-id-type="pmid">23473350</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Tsuchiya</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study</article-title>. <source>Int Clin Psychopharmacol</source>
<year>2012</year>; <volume>27</volume>: <fpage>165</fpage>-<lpage>76</lpage>.
<pub-id pub-id-type="pmid">22395527</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loebel</surname><given-names>A</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><name><surname>Pikalov</surname><given-names>A</given-names></name><name><surname>Kane</surname><given-names>JM</given-names></name></person-group>
<article-title>Effectiveness of lurasidone v. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study</article-title>. <source>Schizophr Res</source>
<year>2013</year>; <volume>147</volume>: <fpage>95</fpage>-<lpage>102</lpage>.
<pub-id pub-id-type="pmid">23583011</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harvey</surname><given-names>PD</given-names></name><name><surname>Siu</surname><given-names>CO</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Loebel</surname><given-names>A</given-names></name></person-group>
<article-title>Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension</article-title>. <source>Eur Neuropsychopharmacol</source>
<year>2013</year>; <volume>23</volume>: <fpage>1373</fpage>-<lpage>82</lpage>.
<pub-id pub-id-type="pmid">24035633</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L</given-names></name><name><surname>Weiden</surname><given-names>PJ</given-names></name><name><surname>McEvoy</surname><given-names>JP</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study</article-title>. <source>CNS Spectr</source>
<year>2013</year>
<month>12</month>
<day>16</day>:<fpage>1</fpage>-<lpage>10</lpage>
<comment>[Epub ahead of print]</comment>.
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Simonelli</surname><given-names>D</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Pikalov</surname><given-names>A</given-names></name><name><surname>Loebel</surname><given-names>A</given-names></name></person-group>
<article-title>Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study</article-title>. <source>J Clin Psychiatry</source>
<year>2013</year>; <volume>74</volume>: <fpage>507</fpage>-<lpage>15</lpage>.
<pub-id pub-id-type="pmid">23541189</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tandon</surname><given-names>R</given-names></name><name><surname>Loebel</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Pikalov</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>O</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia [abstract]</article-title>. <source>Schizophr Res</source>
<year>2014</year>; <volume>153</volume> (<issue>suppl 1</issue>): <fpage>S372</fpage>.
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group>
<source>Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Latuda (International Non-Proprietary Name: Lurasidone)</source>. <publisher-name>EMA</publisher-name> (<uri xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002713/WC500164684.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002713/WC500164684.pdf</uri>).
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Judd</surname><given-names>LL</given-names></name><name><surname>Akiskal</surname><given-names>HS</given-names></name><name><surname>Schettler</surname><given-names>PJ</given-names></name><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Maser</surname><given-names>J</given-names></name><name><surname>Solomon</surname><given-names>DA</given-names></name><etal/></person-group>
<article-title>The long-term natural history of the weekly symptomatic status of bipolar I disorder</article-title>. <source>Arch Gen Psychiatry</source>
<year>2002</year>; <volume>59</volume>: <fpage>530</fpage>-<lpage>7</lpage>.
<pub-id pub-id-type="pmid">12044195</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ketter</surname><given-names>TA</given-names></name><name><surname>Citrome</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>PW</given-names></name><name><surname>Culver</surname><given-names>JL</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name></person-group>
<article-title>Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?</article-title>
<source>Acta Psychiatr Scand</source>
<year>2011</year>; <volume>123</volume>: <fpage>175</fpage>-<lpage>89</lpage>.
<pub-id pub-id-type="pmid">21133854</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loebel</surname><given-names>A</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Kroger</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study</article-title>. <source>Am J Psychiatry</source>
<year>2014</year>; <volume>171</volume>: <fpage>160</fpage>-<lpage>8</lpage>.
<pub-id pub-id-type="pmid">24170180</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loebel</surname><given-names>A</given-names></name><name><surname>Cucchiaro</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Kroger</surname><given-names>H</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study</article-title>. <source>Am J Psychiatry</source>
<year>2014</year>; <volume>171</volume>: <fpage>169</fpage>-<lpage>77</lpage>.
<pub-id pub-id-type="pmid">24170221</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>&#x000c5;sberg</surname><given-names>M</given-names></name></person-group>
<article-title>A new depression scale designed to be sensitive to change</article-title>. <source>Br J Psychiatry</source>
<year>1979</year>; <volume>134</volume>: <fpage>382</fpage>-<lpage>9</lpage>.
<pub-id pub-id-type="pmid">444788</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belmaker</surname><given-names>RH</given-names></name></person-group>
<article-title>Lurasidone and bipolar disorder</article-title>. <source>Am J Psychiatry</source>
<year>2014</year>; <volume>171</volume>: <fpage>131</fpage>-<lpage>3</lpage>.
<pub-id pub-id-type="pmid">24170243</pub-id></mixed-citation></ref></ref-list></back></article>